Media stories about Advaxis (NASDAQ:ADXS) have been trending positive recently, Alpha One reports. The research group, a unit of Accern, identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advaxis earned a media sentiment score of 0.40 on Alpha One’s scale. Alpha One also assigned news headlines about the biotechnology company an impact score of 50 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Alpha One Sentiment’s rankings:
- EPS for Advaxis, Inc. (ADXS) Expected At $-0.49, Chuys Holdings (CHUY) Shorts Up By 0.29% – High Point Observer (highpointobserver.com)
- 3 Things In Biotech You Should Learn Today: May 18, 2017 (seekingalpha.com)
- Advaxis to Host Investor & Analyst Day on June 12 (finance.yahoo.com)
- Advaxis : Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac (4-traders.com)
- Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : May 15, 2017 (finance.yahoo.com)
Several equities analysts have issued reports on the stock. Cantor Fitzgerald restated a “buy” rating and set a $19.00 target price on shares of Advaxis in a research note on Monday, February 27th. HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Monday, March 13th. Five analysts have rated the stock with a buy rating, Advaxis presently has an average rating of “Buy” and a consensus price target of $24.00.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Friday, March 10th. The biotechnology company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.09. The business had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $2.15 million.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.